St. Jude on Therapeutics: 5 Discoveries to Explore
Scientists at St. Jude are leveraging the latest chemical technology to degrade proteins in a targeted way, thereby removing them from a cell, called proteolysis targeting chimeras (PROTACs). Drs. Jun J. Yang and Zoran Rankovic developed a PROTAC for a target called LCK in high-risk leukemia, effectively eliminating the LCK protein and killing leukemia cells.
Find out more: Targeted protein degradation to treat cancer
The most severe class of epilepsy disorders, developmental and epileptic encephalopathies (DEE), are challenging to treat. At St. Jude, Dr. Heather Mefford is identifying mutations that cause DEE in patients and determining their biological implications to help develop precision therapies.
Find out more: Genomic underpinnings of epilepsy hold therapeutics clues.
One of the fundamental mechanisms of our body, transcription, is how genetic information in DNA is copied into mRNA to be later translated into a protein. At St. Jude, my collaborators and I are investigating how best to design a drug for an undruggable aspect of transcription using bromodomain inhibitors. We developed a series of inhibitors that target the bromodomain and extraterminal (BET) family of proteins, which can potentially treat cancer and other diseases.
Find out more: The road to drugging the undruggable.
The genetic mutation that causes sickle cell disease affects the formation of beta-globin (a subunit of hemoglobin) in red blood cells, causing them to sickle in shape. At St. Jude, Dr. Mitch Weiss is leading research that uses genetic editing to turn on fetal hemoglobin production in adults, circumventing beta-globin. The researchers have published their proof-of-principle showing that in doing so, gene editing techniques could be used to potentially cure sickle cell disease.
Find out more: Gene editing holds the promise of a sickle cell cure.
In the lab, it is possible to design and synthesize molecules to carry out a specific purpose, including synthetic DNA binding molecules. Dr. Aseem Ansari studies such synthetic molecules by mapping their genome-wide binding properties in living cells. His lab discovered that these synthetic genome readers had a longer “dwell time” at genome regions with clusters of the targeted binding site. This realization opened the door for targeting a growing number of diseases that occur because of head-to-tail, tandem repeats of short 3-6 nucleotide sequences in a gene or its regulatory regions.
Find out more: The era of genome-targeted therapeutics.